Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-arm, Japan Expanded Access Program With Lanadelumab (TAK-743) for Japanese Patients With Hereditary Angioedema

NCT04687137 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04687137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04687137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-arm, Japan Expanded Access Program With Lanadelumab (TAK-743) for Japanese Patients With Hereditary Angioedema
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
February 10, 2021
Completion date
June 18, 2022
Enrollment
12 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema